Parkinson’s Disease and Related Disorders Part II
The two volumes on Parkinson’s disease in the Handbook of Clinical Neurology (Series Editors: Michael J. Aminoff, Department of Neurology, University of California, San Francisco, USA; François Boller, National Institutes of Health, Bethesda, USA; Dick F. Swaab, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands) cover a group of disorders that constitute the commonest of neurodegenerative diseases and one that is assuming ever greater importance with the ageing of the population in developed countries. The coverage reflects the dramatic advances in understanding of the biochemical background of parkinsonism and the resulting developments in the pharmacological management of the disease. These volumes give a comprehensive account of the subject for both clinical neurologists and those researching in the neurosciences. Part I covers the scientific background, general aspects of Parkinson’s disease, clinical aspects and etiology. Part II covers the medical and surgical treatment of Parkinson’s disease, complications of therapy and the other parkinsonian syndromes.
Part II of a two volume set on Parkinson's Disease in the Handbook of Clinical Neurology series, which has an unparalleled reputation as the world's most comprehensive source of information in neurology.
International list of contributors including the leading workers in the field.
Describes the advances which have occurred in clinical neurology and the neurosciences, their impact on the understanding of Parkinson's Disease and on patient care.
|Sottotitolo:||Handbook of Clinical Neurology (Series Editors: Aminoff, Boller and Swaab)|
2007, Hardback · 608 Pages · 102 Illustrations
Section 5: Treatment of Parkinson's disease
Physical therapy in Parkinson’s disease. Neuroprotection in Parkinson’s disease: clinical trials. Levodopa. Dopamine agonists. Monoamine oxidase A and B inhibitors in Parkinson’s disease. Anticholinergic medications. Antiglutamatergic drugs in the treatment of Parkinson’s disease. Investigational drugs. The importance of patients groups and collaboration
Section 6: Complications of therapy
Motor and non-motor fluctuations. Levodopa-induced dyskinesias in Parkinson’s disease. Treatment induced mental changes in Parkinson’s disease.
Section 7 Surgical treatment
Ablative surgery for the treatment of Parkinson’s disease. Deep brain stimulation. Transplantation. Gene therapy approaches for the treatment of Parkinson’s disease.
Section 8: Other parkinsonian disease syndromes
Multiple system atrophy. Progressive supranuclear palsy. Corticobasal degeneration. Infectious basis to the pathogenesis of Parkinson’s disease. Toxic causes of Parkinson’s disease. Drug induced parkinsonism. Vascular parkinsonism. Old age and Parkinson’s disease. Other degenerative processes. Hydrocephalus and structural lesions. Calcification of the basal ganglia. Trauma and Parkinson’s disease. Psychogenic parkinsonism. Parkinsonism and dystonia. Dementia with Lewy bodies. Myoclonus and parkinsonism.